Tasca Therapeutics, a biotechnology company leveraging a unique drug discovery platform that identifies and maps novel lipid-binding pockets on proteins to develop new medicines to treat human diseases, has announced a $52 million Series A financing, co-led by Regeneron Ventures and Cure Ventures, with participation by Invus Group. This funding will be used to advance Tasca's novel drug discovery platform, progress its lead program, CP-383, into Phase 1/2 clinical proof-of-concept studies, and to expand its drug candidate pipeline.

Tasca is a privately held biotechnology company focused on discovering and developing small molecule inhibitors of auto-palmitoylated target proteins important in cancer. The Company's lead program, CP-383, is a first-in-class drug candidate, with promising preclinical activity against multiple cancer types.